GCEIP 500 Global rank #49 · United States
AbbVie: a research-led drug company navigating life after Humira
AbbVie’s recent growth has shifted toward newer immunology medicines as Humira faces competition from biosimilars. The transition shows how a pharmaceutical company must replace mature products while funding new research.
The company
What it does
AbbVie researches, develops and sells medicines across immunology, oncology, neuroscience, eye care and aesthetics. It emerged from Abbott in 2013 and has built a portfolio of specialty medicines alongside research programmes in new therapies.
Across markets
AbbVie reported $30.4 billion in global immunology revenue for 2025 and $6.7 billion from oncology medicines. Those commercial figures show the scale of its drug portfolio, but patient impact depends on clinical benefit, safety, access and the availability of alternatives. The company’s product mix is changing as older medicines face competition and newer treatments gain adoption.
The company’s footprint and context are linked to the public sources below.
GCEIP view
What the record tells us
Fortune and Great Place To Work included AbbVie in the 2025 World’s Best Workplaces ranking. That is a workplace ranking, not an award for medicine or company performance. GCEIP’s assessment of its business impact rests on the reach of its treatments and the research pipeline needed to sustain it. Revenue indicates adoption and market scale; independent clinical outcomes and access remain separate measures.
Published recognition
Selected results
See published awards and company-list results 1 sources
- Fortune / Great Place To Work World’s Best Workplaces · 2025View source
Global workplace research ranking
2025 global workplace list, rank 6